Abstract
Patients with metastatic melanoma still experience poor prognosis despite the recent approval of new therapeutic agents. It is therefore essential to continue searching for new therapeutic targets and approaches. In recent year, studies have suggested that the receptor for advanced glycation end products (RAGE) could be a potential therapeutic target in metastatic melanoma. Animal studies have shown that blocking RAGE with targeted antibodies could reduce tumor growth and metastases formation. We will discuss here evidence suggesting that RAGE and its ligands contribute significantly to metastatic melanoma and that blocking RAGE activation could be a valid approach for treating this disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
